Pharmaceuticals company Amrutanjan Health Care announced Q1FY27 results Financial Highlights: Revenue from Operations: For Q1FY27, revenue stood at Rs 10,296.88 lakh, marking a YoY growth of 9.49% compared to Rs 9,404.57 lakh in Q1FY26, while recording a QoQ decrease of 31.25% from Rs 14,976.81 lakh in Q4FY26. Total Income: Total income for the quarter was Rs 10,678.36 lakh, an increase of 8.44% YoY from Rs 9,847.31 lakh in Q1FY26 and a decline of 30.88% QoQ from Rs 15,449.87 lakh in Q4FY26. Profit Before Tax (PBT): PBT reached Rs 606.94 lakh in Q1FY27, representing a YoY decrease of 46.25% from Rs 1,129.27 lakh in Q1FY26 and a QoQ decrease of 71.12% from Rs 2,101.62 lakh in Q4FY26. Net Profit: Profit after tax for Q1FY27 was reported at Rs 436.57 lakh, down 47.47% YoY from Rs 831.12 lakh in Q1FY26 and down 73.04% QoQ from Rs 1,619.28 lakh in Q4FY26. Total Comprehensive Income: The company recorded a total comprehensive income of Rs 401.78 lakh for Q1FY27, showing a YoY decline of 51.33% from Rs 825.49 lakh in Q1FY26 and a QoQ decline of 75.36% from Rs 1,630.47 lakh in Q4FY26. Earnings Per Share (EPS): Basic and Diluted EPS (not annualised) for Q1FY27 stood at Rs 1.51, compared to Rs 2.87 in Q1FY26 and Rs 5.60 in Q4FY26. Business Highlights: Segment Wise Performance: OTC Products: This segment recorded revenue of Rs 5,725.83 lakh in Q1FY27 (compared to Rs 5,697.24 lakh in Q1FY26) and a segment result of Rs 987.44 lakh. Women's Hygiene & Personal Care: The segment reached revenue of Rs 3,635.77 lakh in Q1FY27 (compared to Rs 2,860.75 lakh in Q1FY26) and reported a segment loss of Rs 287.61 lakh. Beverages: Revenue for the quarter was Rs 863.59 lakh (compared to Rs 778.01 lakh in Q1FY26), with a segment loss of Rs 125.98 lakh. Others (Pain Management Centre): Revenue stood at Rs 71.69 lakh for Q1FY27, with a segment result of Rs 3.39 lakh. Exceptional Item: The company recognized an exceptional item of Rs 202.75 lakh during Q1FY27. This represents an additional cost settled by the management following a revised lease rent demand from the HR & CE Department for leasehold land. Dividend: The company has fixed Friday, September 11, 2026, as the record date for determining shareholder eligibility for the payment of the Final Dividend. ESOP Schemes: The 'ESOP 2 Scheme' was withdrawn due to the non-satisfaction of turnover conditions. Subsequently, the Board approved further grants under the 'Second Phase ESOP 2 Scheme' on May 7, 2025. Product Renaming: Pursuant to the launch of new products, the "Women's Hygiene" segment has been renamed "Women's Hygiene & Personal Care." Result PDF
Pharmaceuticals firm Amrutanjan Health Care announced Q1FY23 Result : Key raw material prices excluding Menthol crystal price are higher when compared to Q1 FY22. The prices of packing materials are higher when compared to Q1 FY22. Advertisement spend for Q1 FY23 is at Rs.5.20 cr against Rs.4.28 cr for Q1 FY22. Advertisement spend for Comfy is at 3.90 cr for Q1 FY23 against 3.31 cr for Q1 FY22. Result PDF